Spots Global Cancer Trial Database for adagrasib
Every month we try and update this database with for adagrasib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib | NCT05924152 | Healthy Adults | Adagrasib Eltrombopag + a... | 18 Years - 60 Years | Mirati Therapeutics Inc. | |
| Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | NCT05375994 | Non Small Cell ... KRAS Activating... Advanced Cancer Metastatic Canc... Malignant Neopl... Malignant Neopl... | avutometinib (V... | 18 Years - | Verastem, Inc. | |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | NCT05853575 | Advanced Cancer Metastatic Canc... Malignant Neopl... | Adagrasib | 18 Years - | Mirati Therapeutics Inc. | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | NCT06026410 | Solid Tumors Wi... Non Small Cell ... Colorectal Canc... Pancreatic Duct... Clear Cell Rena... | KO-2806 Cabozantinib Adagrasib | 18 Years - | Kura Oncology, Inc. | |
| A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors | NCT06024174 | Advanced Solid ... | BMS-986466 Adagrasib Cetuximab | 18 Years - | Bristol-Myers Squibb | |
| Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | NCT06248606 | Non Small Cell ... NSCLC KRAS G12C | Adagrasib Stereotactic Ra... | 18 Years - | Hoosier Cancer Research Network | |
| Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies | NCT04418661 | Metastatic Neop... | SAR442720 Pembrolizumab Adagrasib | 18 Years - | Sanofi | |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | NCT03785249 | Advanced Cancer Metastatic Canc... Malignant Neopl... | MRTX849 Pembrolizumab Cetuximab Afatinib | 18 Years - | Mirati Therapeutics Inc. | |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | NCT05853575 | Advanced Cancer Metastatic Canc... Malignant Neopl... | Adagrasib | 18 Years - | Mirati Therapeutics Inc. | |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | NCT04613596 | Advanced Non-Sm... Metastatic Non-... | Adagrasib Adagrasib Adagrasib Adagrasib Pembrolizumab | 18 Years - | Mirati Therapeutics Inc. | |
| Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | NCT04975256 | Advanced Cancer Metastatic Canc... Malignant Neopl... Malignant Neopl... Malignant Neopl... | MRTX849 BI 1701963 | 18 Years - | Mirati Therapeutics Inc. | |
| A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | NCT05848843 | Lung Cancer Gastro-intestin... | Durvalumab Adagrasib | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies | NCT04418661 | Metastatic Neop... | SAR442720 Pembrolizumab Adagrasib | 18 Years - | Sanofi | |
| Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status | NCT05673187 | NSCLC Stage IV KRAS P.G12C | Adagrasib | 18 Years - | ETOP IBCSG Partners Foundation | |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | NCT04613596 | Advanced Non-Sm... Metastatic Non-... | Adagrasib Adagrasib Adagrasib Adagrasib Pembrolizumab | 18 Years - | Mirati Therapeutics Inc. | |
| Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation | NCT05162443 | Advanced Cancer Metastatic Canc... Malignant Neopl... | adagrasib (MRTX... | 18 Years - | Mirati Therapeutics Inc. | |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | NCT03785249 | Advanced Cancer Metastatic Canc... Malignant Neopl... | MRTX849 Pembrolizumab Cetuximab Afatinib | 18 Years - | Mirati Therapeutics Inc. | |
| Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation | NCT05162443 | Advanced Cancer Metastatic Canc... Malignant Neopl... | adagrasib (MRTX... | 18 Years - | Mirati Therapeutics Inc. | |
| A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | NCT06412198 | Metastatic Colo... KRAS G12C Mutat... | Cetuximab Cemiplimab Adagrasib | 18 Years - | M.D. Anderson Cancer Center | |
| Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | NCT06248606 | Non Small Cell ... NSCLC KRAS G12C | Adagrasib Stereotactic Ra... | 18 Years - | Hoosier Cancer Research Network | |
| A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | NCT06412198 | Metastatic Colo... KRAS G12C Mutat... | Cetuximab Cemiplimab Adagrasib | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
